Group 1: Event Overview - The 2025 China Rabies Academic Annual Conference was held in Chongqing, focusing on rabies prevention strategies and control practices, with around 1500 experts in attendance [1] - The theme of the conference was "Moving the Gate Forward, Social Co-Governance, Eliminating Rabies" [1] Group 2: Company and Product Highlights - Xingmeng Biopharmaceutical (Suzhou) Co., Ltd. showcased its innovative product, Kerebi (generic name: Zemeiluo Weima Zuo Wei Monoclonal Antibody Injection), which became a focal point of discussion at the conference [1][2] - Kerebi is the first domestic rabies cocktail monoclonal antibody that meets WHO recommendations, combining Zemeiluo and Ma Zuo Wei in equal amounts, offering unique advantages in neutralizing virus strains [2] Group 3: Clinical Trial Results - Kerebi has undergone six large-scale clinical trials globally, covering 1137 patients, with 978 being high-risk individuals (Level III exposure) [3] - Over 90% of Level III exposure patients achieved effective protection within 24 hours of Kerebi injection, with 99.9% reaching effective protection by day three, significantly surpassing the traditional therapy's 23.3% [3] - A one-year follow-up study indicated a 100% survival rate among patients treated with Kerebi, addressing the "window period" issue between vaccination and antibody production [3] Group 4: Market Reception and Future Prospects - Kerebi has gained significant attention and recognition from various sectors after its approval for domestic market use, with widespread clinical application across hospitals and disease control centers [3] - The CEO of Xingmeng Biopharmaceutical expressed the company's commitment to providing effective treatments for rabies exposure and contributing to rabies control efforts [4]